Bookmarks
BHF Data Science Centre
Datasets (4)
Secure Data Environment for CVD-COVID-UK / COVID-IMPACT (England)
Dataset population size: 57,000,000
Health and disease, Registry, Treatments/Interventions, Measurements/Tests, Socioeconomic, Lifestyle, Environment and energy
Trusted Research Environment for CVD-COVID-UK (Wales)
Dataset population size: 3,200,000
Health and disease, Registry, Treatments/Interventions, Measurements/Tests, Socioeconomic, Lifestyle, Environment and energy
Trusted Research Environment for CVD-COVID-UK (Scotland)
Dataset population size: 5,500,000
Health and disease, Registry, Treatments/Interventions, Measurements/Tests, Socioeconomic, Lifestyle, Environment and energy
Trusted Research Environment for CVD-COVID-UK (Wales + Census)
Dataset population size: 3,200,000
Health and disease, Registry, Treatments/Interventions, Measurements/Tests, Socioeconomic, Lifestyle, Environment and energy
Collections (1)
Analysis Scripts & Software (1)
Data Uses (87)
CCU018: COVID infection during pregnancy on cardiovascular disease and related risk factors
University of Cambridge
CCU014: Assessing the impact of COVID-19 on clinical pathways using a medicines approach
University of Liverpool
CCU013: High-throughput electronic health record phenotyping approaches
University College London
CCU023: Repurposing medicines used to treat CVD risk to prevent COVID-19
University of Liverpool
Publications (54)
Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource.
Wood A, Denholm R, Hollings S, Cooper J, Ip S, Walker V, Denaxas S, Akbari A, Banerjee A, Whiteley W, Lai A, Sterne J, Sudlow C, CVD-COVID-UK consortium.
Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales.
Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, Denholm R, Akbari A, Abbasizanjani H, Torabi F, Omigie E, Hollings S, North TL, Toms R, Jiang X, Angelantonio ED, Denaxas S, Thygesen JH, Tomlinson C, Bray B, Smith CJ, Barber M, Khunti K, Davey Smith G, Chaturvedi N, Sudlow C, Whiteley WN, Wood AM, Sterne JAC, CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study.
Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort
Handy A, Banerjee A, Wood A, Dale CE, Sudlow C, Tomlinson C, Bean D, Thygesen JH, Mizani MA, Katsoulis M, Sofat R, Dobson R, Takhar R, Hollings S, Denaxas S, Walker V.
Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
Whiteley WN, Ip S, Cooper JA, Bolton T, Keene S, Walker V, Denholm R, Akbari A, Omigie E, Hollings S, Di Angelantonio E, Denaxas S, Wood A, Sterne JAC, Sudlow C, CVD-COVID-UK consortium.
COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records.
Thygesen JH, Tomlinson C, Hollings S, Mizani MA, Handy A, Akbari A, Banerjee A, Cooper J, Lai AG, Li K, Mateen BA, Sattar N, Sofat R, Torralbo A, Wu H, Wood A, Sterne JAC, Pagel C, Whiteley WN, Sudlow C, Hemingway H, Denaxas S, Longitudinal Health and Wellbeing COVID-19 National Core Study and the CVD-COVID-UK/COVID-IMPACT Consortium.
Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort.
Handy A, Banerjee A, Wood AM, Dale C, Sudlow CLM, Tomlinson C, Bean D, Thygesen JH, Mizani MA, Katsoulis M, Takhar R, Hollings S, Denaxas S, Walker V, Dobson R, Sofat R, CVD-COVID-UK Consortium.